2‐Phenylquinazolin‐4(3 H )‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis
Archiv der Pharmazie · 2023
DOI: 10.1002/ardp.202200654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Ranza Elrayess und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
New derivatives of 2‐phenylquinazolin‐4(3 H )‐one were designed, synthesized, and biologically evaluated as potent allosteric kinase inhibitors with in situ cytotoxicity against MCF‐7 and HepG2 cells. Compounds 15 and 18 among the proposed compounds showed promising antiproliferative activity against MCF‐7 (IC 50 = 1.35 µM) and HepG2 cells (IC 50 = 3.24 µM), comparable to sorafenib, with IC 50 values of 3.04, 2.93 µM, respectively, according to in situ cytotoxicity testing. Comparing compounds 15 and 18 to sorafenib, the in vitro VEGFR‐2 inhibitory activity displayed encouraging selective efficacy with IC 50 values of 13, 67, and 30 nM, respectively. Results of VEGFR‐2 inhibition at various ATP concentrations proved that there was no statistically significant difference between the IC 50 values, which improved the non‐ATP competitive binding. Compound 15 caused apoptotic breast cancer cell death with 55.11‐fold cell‐cycle arrest at the S‐phase, where it affected the apoptosis‐mediated genes through upregulating P53, Bax, caspases 3, 8, and 9 and downregulating the antiapoptotic gene Bcl‐2. A molecular docking study was conducted to confirm the binding of the designed compounds to the allosteric site of VEGFR‐2 in DFG‐out mode, leaving the ATP‐binding pocket unoccupied when superimposed to the pose of sorafenib. The designed molecules showed resealable binding affinity toward the DFG loop and the allosteric site. Hence, the 2‐phenylquinazolin‐4(3 H )‐one derivative constitutes intriguing starting points for designing apoptotic‐inducing drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
- Chemistry Department (Biochemistry program), Faculty of Science, Suez Canal University, Ismailia, Egypt.
ORCID-Profile: Ranza Elrayess, Mohamed S Elgawish, Mohamed S Nafie, Nagat Ghareb, Asmaa S A Yassen
Zitieren
APA
Elrayess, R., Elgawish, M. S., Nafie, M. S., Ghareb, N., & Yassen, A. S. A. (2023). 2‐Phenylquinazolin‐4(3 H )‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202200654
Vancouver
Elrayess R, Elgawish MS, Nafie MS, Ghareb N, Yassen ASA. 2‐Phenylquinazolin‐4(3 H )‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202200654
BibTeX
@article{Elrayess2023,
author = {Elrayess, Ranza and Elgawish, Mohamed S and Nafie, Mohamed S and Ghareb, Nagat and Yassen, Asmaa S A},
title = {2‐Phenylquinazolin‐4(3 H )‐one scaffold as newly designed, synthesized VEGFR‐2 allosteric inhibitors with potent cytotoxicity through apoptosis},
journal = {Archiv der Pharmazie},
year = {2023},
doi = {10.1002/ardp.202200654}
}
EUVIMED